Posted by Michael Wonder on 29 Jul 2019
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
26 July 2019 - Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival and progression-free survival in over 20 years.
Roche today announced that the EMA's CHMP has adopted a positive opinion for Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer.
